Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
Published Online: 2019-02-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Arnaud Scherpereel•Catherine Ligeza-Poisson•Clarisse Audigier-Valette•David Planchard•Delphine CARMIER•Denis Moro-Sibilot•Didier DEBIEUVRE•Elodie Amour•Florian Guisier•Franck Morin•Gérard Zalcman•Isabelle Monnet•Jacques CADRANEL•Julien Mazieres•Laurent Greillier•Myriam Locatelli-Sanchez•Olivier Bylicki•Olivier Molinier•Pascal Dô•Romain Corre•Sandrine HIRET•Sylvie Lantuejoul•Séverine FRABOULET-MOREAU•Thierry Urban
